Lynch Regenerative Medicine closes financing round A

The company brings proven skin rejuvenation and regeneration solutions to the global skin care market

FRANKLIN, Tenn., July 17, 2024–(BUSINESS WIRE)–Lynch Regenerative Medicine, LLC (LRM) has completed its Series A financing round to develop and commercialize innovative skin rejuvenation and regeneration solutions based on the only tissue growth factor approved by the FDA and other international regulators as safe and effective for human tissue regeneration and wound healing: pure platelet-derived growth factor (PDGF). LRM’s Series A financing round was led by Champion VC, a family office investor that manages the assets of members of the Nashville, Tennessee-based Frist family, and Dr. Samuel Lynch, LRM’s founder and CEO.

The patented pure PDGF-based technology is currently the main active ingredient in four FDA-approved products, including two products to enhance the healing and regeneration of orthopedic tissues and one product each to enhance the healing and regeneration of periodontal tissues and skin. These products have helped millions of patients around the world over the past 15 years. Now LRM is applying this proven technology to skin aesthetics.

Dr. Lynch is one of the most successful founders and CEOs of regenerative medicine companies. LRM is his third company to bring pure PDGF-based products to market. Skin care represents the largest and fastest growing market segment for this technology to date. The market needs safe, effective and proven solutions for rejuvenation and regeneration of healthy skin tissue.

Dr. Lynch, recognized worldwide as one of the leading experts in tissue growth factors, commented, “I have spent my career studying regenerative medicine and developing and commercializing PDGF products to regenerate tissue lost due to trauma or disease. I am most excited to bring pure PDGF-based solutions to the skin care market, where we see the greatest unmet need for proven skin rejuvenation and regeneration solutions.”

LRM’s first product to improve skin aesthetics, Ariessence™ Pure PDGF+ (www.ariessence.com) is available now and is available in leading innovative medical/spa clinics and other aesthetic-focused practices, including dermatology and plastic surgery offices. Ariessence Pure PDGF+ is used topically to enhance the aesthetic results of procedures such as microneedling, dermabrasion, lasers, plastic surgery and other procedures where the appearance of healthier looking skin can be accelerated and enhanced by growth factors such as PDGF.

The story goes on

“Growth factors play an important role in skin care today, but there are no other solutions supported by as much scientific and clinical evidence demonstrating the safety and efficacy of pure PDGF,” said Lynch. “Arriessence Pure PDGF+ builds on this truly unique foundation of success in regenerative medicine.”

LRM will use the capital from the Series A financing to advance its commercialization strategy. Following the successful completion of this Series A round, LRM plans to expand its team and hire additional top talent across multiple disciplines, including commercialization, business development, clinical development and regulatory affairs.

PH Partners acted as financial advisor to LRM and Bass, Berry & Sims acted as legal advisors in connection with the transaction.

Lynch Regenerative Medicine, LLC is pioneering innovative treatments designed to revolutionize the $100 billion aesthetic and wound care market. Our mission is to leverage our heritage in regenerative medicine and our decades-long commitment to safe and effective regenerative products of the highest quality to deliver exceptional results to our clients and their patients, redefining the future of aesthetic regenerative medicine. Founded in 2023, the company is based in Franklin, Tennessee.

View original version on businesswire.com: https://www.businesswire.com/news/home/20240717195845/en/

contacts

Nancy Rocco, [email protected]; (888) 576-7343.